Antisoma starts NSCLC Phase II

Antisoma (LSE:ASM) started an open-label, international Phase II trial of AS1404 in combination with carboplatin and paclitaxel in about 70 stage III or IV non-small cell lung cancer (NSCLC) patients who have not received prior chemotherapy. The endpoints include response rate, duration of stable disease, time to progression and median and one-year survival. Initial data are expected in the second half of 2005. ...